These two ASX brain health stocks, boosted by FDA’s approval of Adulhelm, are kicking off clinical trials
Health & Biotech
Health & Biotech
Link copied to
Leading the stocks that got a boost that morning was Cogstate (ASX:CGS), a partner of Eisai which is in turn a partner with Biogen, which developed Aduhelm. It and the FDA itself predicted it would lead to increased investment in this space and perhaps we are starting to see it now.
Today the company revealed it had enrolled the first patient in a clinical trial of its XanaMIA drug against Mild Cognitive Impairment (MCI) due to Alzheimer’s.
The study will run across four outpatient sites across Australia and enrol 105 subjects aged between 50 and 80 in a dose-ranging study to confirm the minimum effective dose.
Actinogen said this was a major milestone.
“This trial will add to the considerable safety and efficacy dataset the company has accumulated on Xanamem and will explore the minimally effective dose to be studied in future trials,” said CEO Steven Gourlay.
“I look forward to working with the team to investigate the potential benefits of Xanamem in improving cognition and treating this devastating disease.”
Shares in Actinogen Medical rose nearly 10 per cent this morning and are up nearly 500 per cent this year.
One of the newer players is HitIQ (ASX:HIQ) which only listed a month ago and is fighting concussion.
The company has a deal with the AFL and today launched a partnership with Rugby Australia. Beginning in the Queensland 1st grade competition, players will utilise the technology for the rest of the season and after the trial to use the data to enhance concussion management protocols.
Rugby Australia’s Chief Medical Officer Andrew Gardner said the adoption of HitIQ was part of the game’s commitment to being safe for all participants.
“We hope that the information gained from this program will enhance our current understanding of the mechanisms of injury and allow us to develop appropriate preventative measures,” he said.